Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia; Human Psychopharmacology: Clinical and Experimental; Vol. 35, iss. 4

Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia; Human Psychopharmacology: Clinical and Experimental; Vol. 35, iss. 4

Bibliografiset tiedot
Parent link:	Human Psychopharmacology: Clinical and Experimental Vol. 35, iss. 4.— 2020.— [e2737, 8 p.]
Yhteisötekijä:	Национальный исследовательский Томский политехнический университет Инженерная школа неразрушающего контроля и безопасности Отделение контроля и диагностики
Muut tekijät:	Fedorenko O. Yu. Olga Yurievna, Paderina D. Z. Diana, Loonen A. J. M. Anton, Pozhidaev I. V. Ivan, Boyko A. S., Kornetova E. G. Elena Georgievna, Bokhan N. A. Nikolay Aleksandrovich, Wilffert B. Bob, Ivanova S. A. Svetlana Aleksandrovna
Yhteenveto:	Title screen Objective: Schizophrenia is a severe highly heritable mental disorder. Genetic polymorphisms of dopaminergic pathways are related to pathogenesis of drug response. Hyperprolactinemia (HPRL), a common adverse effect of antipsychotics, is attributed to blockade of dopamine D2 receptors. Ankyrin Repeat and Kinase Domain containing 1 (ANKK1) gene is closely related to Dopamine Receptor D2 type (DRD2) gene functioning. We examined whether the functional polymorphism rs2734849 in the ANKK1 gene is associated with antipsychotic?induced HPRL. Methods: We recruited 446 patients with schizophrenia from among the Russian population of the Siberian region. The polymorphism rs2734849 in the ANKK1 gene was genotyped with The MassARRAY® Analyzer 4 by Agena Bioscience™, using the kit SEQUENOM Consumables iPLEXGold 384. Genotype and allele frequencies were compared between groups of schizophrenia patients with and without HPRL using the ?2 test. Results: A comparison between schizophrenia patients with and without HPRL revealed significantly higher frequency of the C allele of the polymorphic variant rs2734849 in the ANKK1 gene in patients with HPRL as compared to the patients without it (?2 = 3.70; p = .05; odds ratio [OR] = 1.30 [0.99–1.69]).
Kieli:	englanti
Julkaistu:	2020
Aiheet:	электронный ресурс труды учёных ТПУ ANKK1 hyperprolactinemia polymorphism schizophrenia полиморфизм шизофрения
Linkit:	https://doi.org/10.1002/hup.2737
Aineistotyyppi:	Elektroninen Kirjan osa
KOHA link:	https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=662600

Samankaltaisia teoksia

Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia; Physiology and Pharmacology; Vol. 21, iss. 1
Julkaistu: (2017)

NMDA glutamate receptor polymorphisms modulate antipsychotic-induced hyperprolactinemia in schizophrenia; Progress in Neuro-Psychopharmacology and Biological Psychiatry; Vol. 143
Julkaistu: (2025)

Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia; The World Journal of Biological Psychiatry; Vol. 18, iss. 3
Julkaistu: (2016)

Prolactin gene polymorphism (- 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics; Schizophrenia Research; Vol. 182
Julkaistu: (2017)

Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia; The Application of Clinical Genetics; Vol. 13
Julkaistu: (2020)

Genetic polymorphisms of PIP5K2A and course of schizophrenia; BMC Medical Genetics; Vol. 21
Julkaistu: (2020)

No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic‐induced tardive dyskinesia; Human Psychopharmacology: Clinical and Experimental; Vol. 34, iss. 1
Julkaistu: (2019)

Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors; The World Journal of Biological Psychiatry; Latest Articles
Julkaistu: (2018)

A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia; Progress in Neuro-Psychopharmacology and Biological Psychiatry; Vol. 105
Julkaistu: (2021)

Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome; Frontiers in Psychiatry; Vol. 10
Julkaistu: (2019)

Association between 8 P‐glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug‐induced hyperprolactinaemia; British Journal of Clinical Pharmacology; Vol. 86, iss. 9
Julkaistu: (2020)

A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia; BMC Medical Genetics; Vol. 20
Julkaistu: (2019)

Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression; Frontiers in Pharmacology; Vol. 10
Julkaistu: (2019)

Новый взгляд на генетику нейрокогнитивного дефицита при шизофрении; Журнал неврологии и психиатрии им. C. C. Корсакова; Т. 120, № 8
Tekijä: Федоренко О. Ю. Ольга Юрьевна
Julkaistu: (2020)

Glutamate Concentration in the Serum of Patients with Schizophrenia; Procedia Chemistry; Vol. 10 : Chemistry and Chemical Engineering in XXI century
Julkaistu: (2014)

Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia; Heliyon; Vol. 5, iss. 7
Julkaistu: (2019)

Association of PIP4K2A Polymorphisms with Alcohol Use Disorder; Genes; Vol. 12, iss. 10
Julkaistu: (2021)

Experimental Simulation of LDPE Structure Polymorphism Occurrence Reasons; Journal of Chemistry and Chemical Engineering; Vol. 2, № 1
Julkaistu: (2015)

Ассоциация полиморфизмов гена СОМТ с болезнью Паркинсона; Бюллетень сибирской медицины; Т. 16, № 3
Julkaistu: (2017)

Salts of barbituric and 2-thiobarbituric acids with imidazole: polymorphism, supramolecular structure, thermal stability and water solubility; New Journal of Chemistry; Vol. 47, iss. 47
Julkaistu: (2023)

Neurobiological mechanisms associated with antipsychotic drug-induced dystonia; Journal of Psychopharmacology; Vol. 35, iss. 1
Tekijä: Loonen A. J. M. Anton
Julkaistu: (2021)

Полиморфизмы гена NMDA-рецептора у больных с шизофренией с тардивной дискинезией; Фундаментальные исследования; № 1, ч. 2
Julkaistu: (2015)

Cytotoxic, Genotoxic, and Polymorphism Effects on Vanilla planifolia Jacks ex Andrews after Long-Term Exposure to Argovit® Silver Nanoparticles; Nanomaterials; Vol. 8, iss. 10
Julkaistu: (2018)

An association of AKT1 gene polymorphism with antidepressant treatment response; The World Journal of Biological Psychiatry; Vol. 17, iss. 3
Julkaistu: (2016)

Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia; Journal of Pharmacy and Pharmaceutical Sciences (JPPS); Vol. 21
Julkaistu: (2018)

Study of OH- Radicals in Human Serum Blood of Healthy Individuals and Those with Pathological Schizophrenia; International journal of molecular sciences; Vol. 12, iss. 1
Julkaistu: (2011)

The Effect of Nanoscale Mesoscopic Structural States Associated with Lattice Curvature on the Mechanical Behavior of Ti–6Al–4V Alloy; Physical Mesomechanics; Vol. 23, iss. 6
Julkaistu: (2020)

Dried blood spot analysis for therapeutic drug monitoring of Clozapine; The Journal of Clinical Psychiatry; Vol. 78, iss. 9
Julkaistu: (2017)

Association of Polymorphisms of Serotonin Transporter (5HTTLPR) and 5-HT2C Receptor Genes with Criminal Behavior in Russian Criminal Offenders; Neuropsychobiology; Vol. 75, iss. 4
Julkaistu: (2017)

Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment-free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design; Human Psychopharmacology: Clinical and Experimental; Vol. 37, iss. 3
Julkaistu: (2022)

Карбонаты кальция в холелитах; Известия Томского политехнического университета [Известия ТПУ]; Т. 326, № 1 : Ресурсы планеты
Tekijä: Машина Е. В. Екатерина Валерьевна
Julkaistu: (2015)

Хрестоматия по патопсихологии: учебное пособие
Julkaistu: (Москва, Изд-во МГУ, 1981)

Soteria im Gesprach: Uber eine alternative Schizophreniebehandlung
Tekijä: Aebi E. Elisabeth
Julkaistu: (Bonn, Psychiatrie-Verlag, 1996)

5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia; Frontiers in Molecular Neuroscience; Vol. 13
Julkaistu: (2020)

Полиморфизм генов CYP1A2, CYP2D6 у больных шизофренией с лекарственно-индуцированными нейролептическими побочными эффектами; Бюллетень экспериментальной биологии и медицины; Т. 160, № 11
Julkaistu: (2015)

Исследование ассоциаций полиморфных вариантов генов системы цитохромов Р-450 и гена белка множественной лекарственной устойчивости с развитием лекарственно-индуцированной гиперпролактинемии при шизофрении; Перспективы развития фундаментальных наук; Т. 4 : Биология и фундаментальная медицина
Tekijä: Пожидаев И. В.
Julkaistu: (2017)

Психотерапевтическая динамика в аналитической группе
Tekijä: Мучник М. М. Марина Моисеевна
Julkaistu: (Томск, Раско, 2001)

Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium; Molecular Psychiatry; Vol. 24, iss. 8
Julkaistu: (2019)

Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations; SAGE Open Medicine; Vol. 4
Julkaistu: (2016)

Антитела к нативной и денатурированной ДНК в сыворотке крови больных шизофренией в зависимости от клинических особенностей заболевания; Экспериментально-теоретические вопросы; Т. 116, № 4
Julkaistu: (2016)